Home » Topics » BioWorld Science

BioWorld Science
RSS

bluebird bio and Gritstone Oncology establish cancer cell therapy collaboration

Aug. 24, 2018

FDA approves Inveltys for post-operative inflammation and pain

Aug. 24, 2018

Telix submits CTA to begin phase III trial in Europe with TLX-250 for renal cancer imaging

Aug. 24, 2018

FDA approves Diacomit for seizures associated with Dravet syndrome

Aug. 24, 2018

FDA approves Takhzyro for prevention of HAE attacks

Aug. 24, 2018

DSMB completes new review of safety data from FOCUS trial of melphalan/HDS

Aug. 24, 2018

New selective Mcl-1 inhibitors with in vivo activity described by Vanderbilt University

Aug. 24, 2018

University of South Australia discloses cyclin-dependent kinase inhibitors

Aug. 24, 2018

N-acetyl-beta-D-glucosaminidase inhibitors identified at Janssen

Aug. 24, 2018

Yangzhou Blue Biomedical Technology Co. patents penicilone derivatives

Aug. 24, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...